Dermal Cell News Volume 10.22 | Dec 9 2024

    0
    106







    2024-12-09 | DCN 10.22


    Dermal Cell News by STEMCELL Technologies
    Vol. 10.22 – 9 December, 2024
    TOP STORY

    Dietary Fructose Enhances Tumor Growth Indirectly via Interorgan Lipid Transfer

    Scientists discovered that fructose supplementation enhanced tumour growth in animal models of melanoma, breast cancer, and cervical cancer without causing weight gain or insulin resistance.
    [Nature]

    AbstractPress Release
    Activate, expand, and differentiate your cells with cytokines, chemokines, and growth factors from STEMCELL Technologies.
    PUBLICATIONSListed by the impact factor of the journal

    Dysregulation in Keratinocytes Drives Systemic Lupus Erythematosus Onset

    Investigators found that the level of peroxisome proliferator-activated receptor gamma was substantially reduced in the skin lesions of patients, and replicating this reduction in mice led to rapid disease onset with multiple hallmarks of systemic lupus erythematosus.
    [Cellular & Molecular Immunology]

    Abstract

    Vasculogenic Skin Reprogramming Requires TET-Mediated Gene Demethylation in Fibroblasts for Rescuing Impaired Perfusion in Diabetes

    Human dermal fibroblasts responded to Etv2, Foxc2, and Fli1 nanoelectroporation with elevated expression of endothelial genes in vitro, which was linked to increased ten-eleven translocase 1/2/3 (TET) expression.
    [Nature Communications]

    Full Article

    Melanocortin 1 Receptor Mediates Melanin Production by Interacting with the BBSome in Primary Cilia

    Researchers showed that ultraviolet and α-melanocyte-stimulating hormone triggered cilium formation in human melanocytes and melanoma cells.
    [PLOS Biology]

    Full Article

    YTHDF2 Contributes to Psoriasis by Promoting Proliferation and Inflammatory Response Through Regulation of the Wnt Signaling Pathway

    Subsequent silencing of YT521-B homology domain family 2 (YTHDF2) in a psoriatic cell model resulted in a marked decrease in mRNA expression of IL-17A, S100A8, and S100A9, accompanied by a reduction in cell proliferation. Conversely, overexpression of YTHDF2 led to the opposite effects.
    [International Immunopharmacology]

    Abstract

    Atorvastatin Calcium Alleviates UVB-Induced HaCat Cell Senescence and Skin Photoaging

    Through in vitro experiments with human immortalized keratinocytes (HaCat), researchers found that atorvastatin calcium could significantly reduce the ultraviolet radiation B-induced increased expression of age-related protein p16 and age-related gene p21.
    [Scientific Reports]

    Full Article

    Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma

    Scientists used genetically engineered mouse models and patient-derived BRAFV600E-driven melanoma cell lines to dissect the role of PREX2 in melanomagenesis and response to therapy.
    [Cancer Research]

    Abstract

    Setdb1-Loss Induces Type-I Interferons and Immune Clearance of Melanoma

    To identify tumor-intrinsic modulators of immunity to melanoma, researchers performed a whole-genome CRISPR screen in melanoma and identified Setdb1 as well as all components of the HUSH complex.
    [Cancer Immunology Research]

    Full Article

    The Efficacy and Safety of First-Line Metastatic Melanoma Treatment with Ipilimumab + Nivolumab Versus Nivolumab in a Real-World Setting

    Investigators compared the efficacy and safety of nivolumab to ipilimumab + nivolumab as first-line treatment for metastatic melanoma. A total of 406 patients were treated with nivolumab, and 416 with ipilimumab + nivolumab.
    [British Journal of Dermatology]

    Abstract
    Generate More Proliferative Human Keratinocytes with DermaCult â„¢
    REVIEWS

    Unveiling Intricating Roles and Mechanisms of Ferroptosis in Melanoma

    The authors emphasize the roles and regulatory mechanisms of ferroptosis in melanoma development, the involved immune regulation, as well as the potential for diagnosis and treatment of melanoma.
    [Biochimica et Biophysica Acta-Reviews on Cancer]

    Abstract
    INDUSTRY AND POLICY NEWS

    AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer

    AiViva Biopharma, Inc. announced the receipt of FDA clearance for testing AIV001 by intradermal injection with their formulation in facial skin. AIV001 is a pan-tyrosine kinase inhibitor in a proprietary formulation, designed for prolonged drug release.
    [AiViva Biopharma, Inc. (GlobeNewswire)]

    Press Release
    FEATURED EVENT

    Conference on Advancements in Organoid Sciences

    January 30-31, 2025 Hamburg, Germany

    > See All Events

    JOB OPPORTUNITIES

    Research Assistant – Malignant Melanoma

    Karolinska Institute – Solna, Sweden

    PhD Studentship – Development of Novel Drug Combinations

    University of Bradford – Bradford, England, United Kingdom

    PhD Studentship – Chronic Skin Infections

    Ulster University – Belfast, Northern Ireland, United Kingdom

    Postdoctoral Contract – Skin Cancer and TME

    Spanish National Cancer Research Center – Madrid, Spain

    Faculty Position – Translational Cancer Research

    Northwell Health – Manhasset, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2